Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spectral Medical ( (TSE:EDT) ) has provided an announcement.
Spectral Medical and Vantive announced positive topline results from the Tigris trial, a Phase 3 study evaluating PMX Hemoadsorption Therapy for endotoxic septic shock. The trial demonstrated a significant reduction in 28-day and 90-day mortality rates, exceeding the prespecified primary endpoint with a high probability of benefit, which could enhance Spectral’s positioning in the sepsis treatment market.
Spark’s Take on TSE:EDT Stock
According to Spark, TipRanks’ AI Analyst, TSE:EDT is a Neutral.
Spectral Medical’s overall stock score is primarily impacted by its weak financial performance and valuation concerns, which are significant risks. However, positive corporate events, including progress towards FDA approval and securing funding, provide a potential upside. Technical analysis shows mixed signals, with some longer-term support but short-term weaknesses.
To see Spark’s full report on TSE:EDT stock, click here.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. Vantive is a company dedicated to developing novel diagnostic and therapeutic options for organ failure.
Average Trading Volume: 56,933
Technical Sentiment Signal: Buy
Current Market Cap: C$231.5M
See more insights into EDT stock on TipRanks’ Stock Analysis page.